There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Healthcare Services (HCSG – Research Report), Thermo Fisher (TMO – Research Report) and Boston Scientific (BSX – Research Report) with bullish sentiments.
Healthcare Services (HCSG)
RBC Capital analyst Sean Dodge maintained a Buy rating on Healthcare Services yesterday and set a price target of $14.00. The company’s shares closed last Wednesday at $10.58.
According to TipRanks.com, Dodge is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -6.4% and a 41.0% success rate. Dodge covers the Healthcare sector, focusing on stocks such as Privia Health Group, Avid Bioservices, and Health Catalyst.
Healthcare Services has an analyst consensus of Moderate Buy, with a price target consensus of $14.33.
See the top stocks recommended by analysts >>
Thermo Fisher (TMO)
RBC Capital analyst Conor McNamara maintained a Buy rating on Thermo Fisher yesterday and set a price target of $718.00. The company’s shares closed last Wednesday at $576.49.
According to TipRanks.com, McNamara is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -9.9% and a 35.4% success rate. McNamara covers the Healthcare sector, focusing on stocks such as Maravai Lifesciences Holdings, Bio-Rad Laboratories, and SOPHiA GENETICS.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Thermo Fisher with a $659.53 average price target, a 14.8% upside from current levels. In a report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $686.00 price target.
Boston Scientific (BSX)
Citi analyst Joanne Wuensch reiterated a Buy rating on Boston Scientific today. The company’s shares closed last Wednesday at $87.45, close to its 52-week high of $88.79.
According to TipRanks.com, Wuensch is a 5-star analyst with an average return of 6.4% and a 63.7% success rate. Wuensch covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Bausch + Lomb Corporation, and Zimmer Biomet Holdings.
Currently, the analyst consensus on Boston Scientific is a Strong Buy with an average price target of $94.22, representing a 10.5% upside. In a report issued on October 14, BTIG also maintained a Buy rating on the stock with a $93.00 price target.
Read More on HCSG: